Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

2.6K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.6K
Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

4
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
4
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

740
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
740
Cancer Vaccines01:30

Cancer Vaccines

1.4K
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.4K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

6.4K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.4K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

1.9K
1.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Neuropsychological Performance in Autoimmune Limbic Encephalitis: Evidence from an Immunotherapy-Naïve Cohort.

Archives of clinical neuropsychology : the official journal of the National Academy of Neuropsychologists·2022
Same author

How patients with multiple sclerosis acquire disability.

Brain : a journal of neurology·2022
Same author

Increased Intrathecal B and Plasma Cells in Patients With Anti-IgLON5 Disease: A Case Series.

Neurology(R) neuroimmunology & neuroinflammation·2022
Same author

Neonatal Fc Receptor-Targeted Therapies in Neurology.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics·2022
Same author

Subcortical Volumes as Early Predictors of Fatigue in Multiple Sclerosis.

Annals of neurology·2021
Same author

Next-generation antibody-based therapies in neurology.

Brain : a journal of neurology·2021

Related Experiment Video

Updated: Apr 21, 2026

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

13.0K

Immunotherapy of multiple sclerosis.

Sven G Meuth1, Stefan Bittner1, Heinz Wiendl1

  • 1Department of Neurology, University of Würzburg, Würzburg, Germany.

Acta Neuropsychiatrica
|November 12, 2014
PubMed
Summary
This summary is machine-generated.

Multiple sclerosis (MS) treatments are advancing with new oral therapies showing promise. Early intervention with immunomodulatory drugs like interferon beta and glatiramer acetate is key for managing this autoimmune CNS disorder.

More Related Videos

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis
06:19

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

4.9K
Intralymphatic Immunotherapy and Vaccination in Mice
07:33

Intralymphatic Immunotherapy and Vaccination in Mice

Published on: February 2, 2014

24.3K

Related Experiment Videos

Last Updated: Apr 21, 2026

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

13.0K
Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis
06:19

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

4.9K
Intralymphatic Immunotherapy and Vaccination in Mice
07:33

Intralymphatic Immunotherapy and Vaccination in Mice

Published on: February 2, 2014

24.3K

Area of Science:

  • Neurology
  • Immunology
  • Pharmacology

Background:

  • Multiple sclerosis (MS) is a primary inflammatory autoimmune disorder of the central nervous system (CNS).
  • It leads to significant neurological disability, particularly in young adults.
  • Current standard therapies include interferon beta and glatiramer acetate, with early treatment recommended.

Purpose of the Study:

  • To review the evolving landscape of multiple sclerosis therapeutics.
  • To highlight the emergence and evaluation of novel oral therapies for MS.
  • To discuss the potential impact of new treatments on MS management.

Main Methods:

  • Review of current literature and ongoing clinical trials.
  • Analysis of emerging oral immunomodulatory agents for MS.
  • Synthesis of evidence regarding therapeutic advancements in MS.

Main Results:

  • Established therapies like interferon beta and glatiramer acetate are effective but not universally sufficient.
  • Significant progress has been made in developing orally administered MS drugs.
  • Several oral agents, including cladribine, teriflunomide, laquinimod, fingolimod, and fumaric acid, are in late-stage clinical trials.

Conclusions:

  • The development of oral therapies represents a major advancement in MS treatment.
  • These new options are expected to expand therapeutic choices for patients with MS.
  • Continued research and clinical trials are crucial for optimizing MS management strategies.